United-Guardian(US:UG)2025-11-06 14:00Sales Performance - Sales for the nine-month period ended September 30, 2025, decreased to $7,583,613 from $9,705,262 in 2024, representing a decline of approximately 22.0%[2] - Third quarter sales fell to $2,264,261 in 2025 from $3,060,113 in 2024, a decrease of approximately 26.0%[2] - Sales of pharmaceutical products increased by 10% and medical products by 6% during the first nine months of 2025 compared to the same period in 2024[3] Net Income - Net income for the nine months ended September 30, 2025, decreased to $1,456,162 ($0.32 per share) from $2,747,151 ($0.60 per share), a decrease of about 47.1%[2] - Net income for the third quarter of 2025 was $268,441 ($0.06 per share), down from $865,484 ($0.19 per share) in the same quarter of 2024, a decline of about 69.0%[2] Cost Management - Total costs and expenses for the nine months ended September 30, 2025, were $6,062,166, down from $6,614,849 in 2024[8] - Research and development expenses for the nine months ended September 30, 2025, were $339,366, slightly up from $325,714 in 2024[8] Market Challenges and Opportunities - The decrease in cosmetic ingredient sales in the third quarter was primarily due to reduced purchases by Ashland Specialty Ingredients, attributed to tariff and geopolitical concerns in Asia[3] - United-Guardian is working with an outside pharmaceutical consultant to increase sales of Renacidin by including it in additional drug formularies, which is expected to significantly boost sales in the coming years[3] - New marketing agreements for personal care products have been negotiated, providing opportunities for revenue growth in the future[3]